Matthew D. Blackledge1, Dow-Mu Koh1, Anwar R. Padhani2, James J. Stirling2, N J. Taylor2, David J. Collins1, Martin O. Leach1
1CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; 2Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, London, United Kingdom
There is currently no standard for evaluating response of bone metastases to novel therapeutics, greatly inhibiting pharmaceutical development. In this feasibility study we investigate the role of tumour burden estimates and apparent diffusion coefficients measured using whole body diffusion weighted imaging (WBDWI) for monitoring treatment response. Good correlations are found between final clinical outcome in patients diagnosed with bone metastases and changes in median ADC value and tumour burden, as predicted using semi-automatic segmentation methods. It is concluded that such measurements from WBDWI will provide a useful tool in future clinical trials.